Cardiff Oncology, Inc. (CRDF)
$0.97-$0.02 (-1.74%) Today
Latest CRDF Insider Trades
Gary W. PaceOpen-market purchase
Gary W. PaceGary W. PaceGary W. PaceGary W. PaceGary W. PaceCardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
https://www.cardiffoncology.comSEC filings for CRDF on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 6 | 1,498,001 | $1.12M |
| Grant or award | 5 | 202,825 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
26 Form 4 filings on record, the earliest from Dec 12, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Gary W. Pace | Open-market purchase | Common Stock | 687,285 | $1.46 | $1.00M | |
| Gary W. Pace | Open-market purchase | Common Stock Purchase Warrant | 687,285 | $0.00 | - | |
| Mani Mohindru - Officer | Open-market purchase | Common Stock | 34,364 | $1.46 | $50K | |
| Mani Mohindru - Officer | Open-market purchase | Common Stock Purchase Warrant | 34,364 | $0.00 | - | |
| Mani Mohindru - Officer | Open-market purchase | Common Stock | 24,703 | $1.21 | $30K | |
| Gary W. Pace | Open-market purchase | Common Stock | 30,000 | $1.22 | $37K | |
| James O. Armitage | Grant or award | Stock Options | 40,565 | $0.00 | - | |
| Lale White | Grant or award | Stock Options | 40,565 | $0.00 | - | |
| Renee P. Tannenbaum | Grant or award | Stock Options | 40,565 | $0.00 | - | |
| Gary W. Pace | Grant or award | Stock Options | 40,565 | $0.00 | - | |
| Rodney S. Markin | Grant or award | Stock Options | 40,565 | $0.00 | - | |
 Ajay Aggarwal - Officer | Grant or award | Stock Options | 400,000 | $0.00 | - | |
 Joshua B. Muntner - Officer | Grant or award | Stock Options | 486,650 | $0.00 | - | |
| Tod Smeal - Officer | Grant or award | Stock Options | 300,000 | $0.00 | - | |
| Joshua B. Muntner - Officer | Grant or award | Stock Options | 486,650 | $0.00 | - | |
| Mani Mohindru - Officer | Grant or award | Stock Options | 600,000 | $0.00 | - | |
| Brigitte Ute Lindsay - Officer | Grant or award | Stock Options | 200,000 | $0.00 | - | |
| Mani Mohindru - Officer | Grant or award | Stock Options | 200,000 | $0.00 | - | |
| Gary W. Pace | Open-market purchase | Common Stock | 275,000 | $2.45 | $674K | |
| Gary W. Pace | Open-market purchase | Common Stock | 15,000 | $2.45 | $37K | |
| Lale White - Director | Grant or award | Stock Options | 40,565 | $0.00 | - | |
| Gary W. Pace - Director | Grant or award | Stock Options | 40,565 | $0.00 | - | |
| Mani Mohindru - Director | Grant or award | Stock Options | 40,565 | $0.00 | - | |
| Rodney S. Markin - Director | Grant or award | Stock Options | 40,565 | $0.00 | - | |
| James O. Armitage - Director | Grant or award | Stock Options | 40,565 | $0.00 | - | |
| Renee P. Tannenbaum - Director | Grant or award | Stock Options | 40,565 | $0.00 | - | |
| James E. Levine - Officer | Open-market purchase | Common Stock | 2,564 | $3.83 | $10K | |
| James E. Levine - Officer | Open-market purchase | Common Stock | 2,752 | $5.42 | $15K | |
| James E. Levine - Officer | Open-market purchase | Common Stock | 2,400 | $5.00 | $12K | |
| Renee P. Tannenbaum | Open-market purchase | Common Stock | 10,000 | $3.42 | $34K | |
| Gary W. Pace | Open-market purchase | Common Stock | 350,115 | $2.60 | $910K | |
| Gary W. Pace | Open-market purchase | Common Stock | 11,500 | $2.60 | $30K |
Cardiff Oncology, Inc. (CRDF) had 9 insider filings in the last 90 days, with the most recent on 2026-07-16. The full record for CRDF runs to 26 Form 4 filings, the earliest from 2024-12-12. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
6 insider purchases of CRDF were filed in the last 90 days, totaling $1.12M.
No insider sales of CRDF were filed in the last 90 days.
This page tracks CRDF Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CRDF to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
